250 related articles for article (PubMed ID: 15603862)
1. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Neubauer MA; Garfield DH; Kuerfler PR; Raju RN; Lindquist DL; Soo EW; Khan M; Boehm KA; Asmar L;
Lung Cancer; 2005 Jan; 47(1):121-7. PubMed ID: 15603862
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer.
Kalmadi S; McNeill G; Davis M; Peereboom D; Adelstein D; Mekhail T
Med Oncol; 2006; 23(4):507-13. PubMed ID: 17303909
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer: a phase II trial of sequential chemotherapy.
Cobo Dols M; Villar Chamorro E; Alés Díaz I; Gil Calle S; Alcalde García J; Gutiérrez Calderón V; Carabantes Ocón F; Montesa Pino A; Bretón García JJ; Benavides Orgaz M
Clin Transl Oncol; 2006 Oct; 8(10):742-9. PubMed ID: 17074673
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of gemcitabine and docetaxel in patients with chemotherapy-naive, advanced nonsmall cell lung carcinoma.
Popa IE; Stewart K; Smith FP; Rizvi NA
Cancer; 2002 Oct; 95(8):1714-9. PubMed ID: 12365019
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel/gemcitabine or cisplatin/gemcitabine followed by docetaxel in the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC): results of a multicentre randomized phase II trial.
Binder D; Schweisfurth H; Grah C; Schäper C; Temmesfeld-Wollbrück B; Siebert G; Suttorp N; Beinert T
Cancer Chemother Pharmacol; 2007 Jun; 60(1):143-50. PubMed ID: 17031643
[TBL] [Abstract][Full Text] [Related]
6. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study.
Kakolyris S; Papadakis E; Tsiafaki X; Kalofonos C; Rapti A; Toubis M; Bania E; Kouroussis C; Chainis K; Androulakis N; Agelaki S; Sarra E; Vardakis N; Georgoulias V;
Lung Cancer; 2001 May; 32(2):179-87. PubMed ID: 11325489
[TBL] [Abstract][Full Text] [Related]
8. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.
Niho S; Kubota K; Goto K; Ohmatsu H; Matsumoto T; Kakinuma R; Nishiwaki Y
Cancer Chemother Pharmacol; 2003 Jul; 52(1):19-24. PubMed ID: 12712259
[TBL] [Abstract][Full Text] [Related]
9. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial.
Hainsworth JD; Erland JB; Barton JH; Thompson DS; Stagg MP; Bradof JE; Twele TW; Greco EA;
Clin Lung Cancer; 2003 Jul; 5(1):33-8. PubMed ID: 14596701
[TBL] [Abstract][Full Text] [Related]
10. Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.
Kubota K; Kawahara M; Ogawara M; Nishiwaki Y; Komuta K; Minato K; Fujita Y; Teramukai S; Fukushima M; Furuse K;
Lancet Oncol; 2008 Dec; 9(12):1135-42. PubMed ID: 19013107
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine plus docetaxel as first-line chemotherapy in patients with advanced non-small cell lung cancer: a lung cancer Galician group phase II study.
Casal J; Amenedo M; Mel JR; Antón LM; Rodríguez-López R; López-López R; González-Ageitos A; Castellanos J; Constenla M; Tisaire JL
Cancer Chemother Pharmacol; 2007 Oct; 60(5):725-32. PubMed ID: 17273825
[TBL] [Abstract][Full Text] [Related]
12. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial.
Spiridonidis CH; Laufman LR; Carman L; Moore T; Blair S; Jones J; George C; Patel T; Roach R; Rupert R; Zangmeister J; Colborn D; Kuebler JP
Ann Oncol; 2001 Jan; 12(1):89-94. PubMed ID: 11249055
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.
Kosmas C; Tsavaris N; Vadiaka M; Stavroyianni N; Koutras A; Malamos N; Onyenadum A; Rokana S; Polyzos A; Kalofonos HP
Cancer; 2001 Dec; 92(11):2902-10. PubMed ID: 11753965
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of days 1 and 8 combination of docetaxel plus gemcitabine for the second-line treatment of patients with advanced non-small-cell lung cancer and good performance status.
Cobo M; Gutiérrez V; Alcaide J; Alés I; Villar E; Gil S; Durán G; Martínez J; Carabantes F; Bretón JJ; Benavides M
Lung Cancer; 2007 May; 56(2):255-62. PubMed ID: 17276537
[TBL] [Abstract][Full Text] [Related]
16. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of weekly docetaxel and gemcitabine for previously untreated, advanced non-small cell lung cancer.
Park SH; Hong J; Kim YS; Kim Y; Kyung SY; An CH; Lee SP; Park JW; Jeong SH; Park J; Cho EK; Shin DB; Lee JH
Lung Cancer; 2008 Oct; 62(1):72-7. PubMed ID: 18342982
[TBL] [Abstract][Full Text] [Related]
18. Front-line treatment of advanced non-small-cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial.
Georgoulias V; Kouroussis C; Androulakis N; Kakolyris S; Dimopoulos MA; Papadakis E; Bouros D; Apostolopoulou F; Papadimitriou C; Agelidou A; Hatzakis K; Kalbakis K; Kotsakis A; Vardakis N; Vlachonicolis J
J Clin Oncol; 1999 Mar; 17(3):914-20. PubMed ID: 10071284
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale.
Galetta D; Gebbia V; Giotta F; Durini E; Romito S; Borsellino N; Cazzato C; Pezzella G; Colucci G
Lung Cancer; 2002 Oct; 38(1):79-84. PubMed ID: 12367797
[TBL] [Abstract][Full Text] [Related]
20. First line chemotherapy with planned sequential administration of gemcitabine followed by docetaxel in elderly advanced non-small-cell lung cancer patients: a multicenter phase II study.
Tibaldi C; Vasile E; Antonuzzo A; Di Marsico R; Fabbri A; Innocenti F; Tartarelli G; Amoroso D; Andreuccetti M; Lo Dico M; Falcone A
Br J Cancer; 2008 Feb; 98(3):558-63. PubMed ID: 18212755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
